Metastatic melanoma is the leading cause of skin cancer deaths in the United States; once melanoma has spread (metastasized), life expectancy for patients can be dramatically shortened. At present, the reference therapy for ...
Mar 13, 2015
0
5
(HealthDay)—In metastatic melanoma, nivolumab improves overall and progression-free survival versus dacarbazine, and dabrafenib plus trametinib improves survival versus vemurafenib monotherapy, according to two studies ...
Nov 18, 2014
0
0
Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, ...
Nov 4, 2014
0
0
A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic ...
Sep 29, 2014
0
0
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according ...
Sep 29, 2014
0
0
Dartmouth researchers have found that the genetic mutation BRAFV600E, frequently found in metastatic melanoma, not only secretes a protein that promotes the growth of melanoma tumor cells, but can also modify the network ...
Sep 11, 2014
0
0
A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive ...
Jul 1, 2014
0
0
For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.
Jun 19, 2014
0
4
(Medical Xpress)—A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.
Jun 3, 2014
0
0
In examining why some advanced melanoma patients respond so well to the experimental immunotherapy MK-3475, while others have a less robust response, researchers at Mayo Clinic in Florida found that the size of tumors before ...
Jun 2, 2014
0
1
